CA
RARE icon

Continuum Advisory’s Ultragenyx Pharmaceutical RARE Stock Holding History

Continuum Advisory’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16
Closed -$673 – 1876
2024
Q4 		$673 Hold
16
– – ﹤0.01% 1690
2024
Q3 		$762 Buy
+16
New +$815 ﹤0.01% 1697

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Continuum Advisory's RARE Position: Q1 2025 in Review

Continuum Advisory sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2025, closing a stake of 16 shares — an estimated $673 sold.

Continuum Advisory first reported a position in RARE in Q3 2024 and held it in 2 quarters. The position peaked at $762 in Q3 2024. 299 funds tracked by Wall St. Rank hold RARE as of Q1 2025.

  • Continuum Advisory reported no remaining Ultragenyx Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Continuum Advisory sold 16 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $673.
  • Continuum Advisory first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and held it in 2 quarters.
  • Continuum Advisory's Ultragenyx Pharmaceutical position peaked at $762 in Q3 2024.
  • 299 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.